Characteristics of the patients with chronic airflow obstruction
| COPD | Asthma | Other RD | |||||
|---|---|---|---|---|---|---|---|
| Emphysema | Yes | No | Yes | No | Yes | No | p Value |
| Number | 517, 40.6% | 104, 8.2% | 178, 13.9% | 169, 13.3% | 128, 10.1% | 176, 13.8% | |
| Age | 69.1±8.3 | 70.4±7.2 | 67.6±7.9 | 64.5±9.5 | 70.6±7.9 | 65.0±11.8 | <0.001 |
| Female sex (n, %) | 20, 3.9 | 10, 9.6 | 21, 11.8 | 55, 32.7 | 4, 3.1 | 66, 37.5 | <0.001 |
| Body mass index | 21.2±3.6 | 23.2±2.6 | 21.9±3.3 | 23.0±3.2 | 22.2±3.6 | 22.3±3.3 | <0.001 |
| Never smoker (n, %) | 0 | 0 | 0 | 62, 36.9 | 0 | 79, 44.9 | <0.001 |
| Smoking index (pack-year) | 67.2±34.7 | 57.6±28.3 | 59.3±29.0 | 22.9±24.5 | 65.8±34.1 | 20.5±25.4 | <0.001 |
| %FVC | 85.5±19.4 | 86.4±18.9 | 86.0±19.2 | 86.1±18.4 | 84.6±22.1 | 76.4±18.5 | <0.001 |
| %FEV1 | 59.6±24.4 | 71.2±21.9 | 56.0±21.8 | 66.5±22.1 | 70.6±28.5 | 65.7±21.3 | <0.001 |
| FEV1/FVC | 44.7±12.7 | 53.3±9.9 | 44.4±11.9 | 52.7±11.1 | 53.2±12.8 | 56.0±11.8 | <0.001 |
| Reversibility, per cent | 8.1±8.1 | 7.7±7.6 | 17.7±13.0 | 17.1±12.3 | 6.8±7.4 | 9.5±10.6 | <0.001 |
| Reversibility, mL | 95.2±85.8 | 108.4±96.5 | 194.4±139.4 | 218.0±158.8 | 96.2±92.9 | 117.4±120.8 | <0.001 |
| δ FEV1 (mL/year) | −34.4±69.8 | −12.9±69.2 | −50.2±59.0 | −12.1±114.5 | −42.8±73.3 | −31.1±93.4 | 0.002 |
| Medication (n, %) | |||||||
| Long-acting β 2-receptor agonist | 164, 31.7% | 31, 29.8% | 93, 52.2% | 122, 72% | 7, 5.5% | 12, 6.8% | <0.001 |
| Long-acting muscarinic receptor antagonist | 181, 35.0% | 29, 27.9% | 48, 27.0% | 4, 2.4% | 17, 13.3% | 4, 2.3% | <0.001 |
| Inhaled corticosteroids | 142, 27.5% | 42, 40.4% | 129, 72.5% | 152, 89.9% | 16, 12.5% | 27, 15.3% | <0.001 |
| Methylxanthine | 60, 11.6% | 13, 12.5% | 37, 20.8% | 22, 13.1% | 22, 17.2% | 12, 6.8% | <0.001 |
| Observation period (year) | 4.3±2.9 | 4.6±3.2 | 5.8±3.2 | 5.9±3.0 | 4.1±2.8 | 4.2±2.8 | <0.001 |
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; RD, respiratory diseases.